Yukin Therapeutics is a French biotechnology company. The company focuses on the development of new therapeutic molecules, entitled kinase inhibitors, specifically targeting a protein involved in the development of several types of cancer: the NIK protein (NF-κB inducing kinase). Yukin Therapeutics led studies that demonstrated proof of concept in animal models and are now actively seeking to identify the first drug candidate to launch a clinical trial in oncology.
Biot, Provence-Alpes-Cote d’Azur
Therapeutics, biotechnology, cancer
Between €2.5 million-5 million
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Yukin Therapeutics? We’re happy to assist you with our Startup Sourcing service.